Therefore, the effective inhibition of BCR-ABL induced by XN could provide a targeted pathway for both sensitive CML as well as that already developing multidrug resistant. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.